Matches in SemOpenAlex for { <https://semopenalex.org/work/W33296887> ?p ?o ?g. }
- W33296887 abstract "The aim of this phase 2 study was to evaluate the safety and efficacy of ixabepilone plus cetuximab in patients with advanced pancreatic cancer.Eligible patients had advanced pancreatic adenocarcinoma that was metastatic or not amenable to resection, a Karnofsky performance status ≥70%, and no prior therapy for advanced disease. Patients received ixabepilone 32 mg/m(2) (3-hour IV infusion) every 3 weeks and cetuximab 250 mg/m(2) (1-hour IV infusion) weekly. The primary efficacy end point was the 6-month survival rate. Secondary end points included tumor response rate, overall survival, progression-free survival, and tolerability.A total of 54 patients were enrolled on this study. The 6-month survival rate was 57% (31/54: 95% CI: 43-71%) with a median overall survival of 7.6 months (95% CI: 5.5-12.2 months). Patients who developed acneiform rash (n = 36) had a median survival of 8.8 months, compared with 2.6 months for those without rash (n = 18). Of 31 patients with measurable disease (defined as response-evaluable), 4 had confirmed partial responses and an additional 24 had stable disease. The combination was generally well-tolerated with the most common grade 3/4 hematological toxicities being leucopenia (39%) and neutropenia (33%). The most common grade 3/4 nonhematologic toxicity was fatigue (17%).The combination of ixabepilone and cetuximab was active and had acceptable toxicity. The efficacy results are similar to single-agent ixabepilone and gemcitabine-based combination therapies in patients with advanced pancreatic cancer. Exploratory analyses suggest a trend toward improved survival for patients who experienced rash." @default.
- W33296887 created "2016-06-24" @default.
- W33296887 creator A5011595369 @default.
- W33296887 creator A5011817630 @default.
- W33296887 creator A5016787975 @default.
- W33296887 creator A5017289995 @default.
- W33296887 creator A5033029344 @default.
- W33296887 creator A5033039101 @default.
- W33296887 creator A5034570679 @default.
- W33296887 creator A5036507892 @default.
- W33296887 creator A5037389732 @default.
- W33296887 creator A5061373605 @default.
- W33296887 creator A5069256182 @default.
- W33296887 creator A5082512772 @default.
- W33296887 date "2012-09-01" @default.
- W33296887 modified "2023-09-23" @default.
- W33296887 title "A phase 2 trial of ixabepilone plus cetuximab in first-line treatment of metastatic pancreatic cancer." @default.
- W33296887 cites W1931508686 @default.
- W33296887 cites W1981120731 @default.
- W33296887 cites W2008803651 @default.
- W33296887 cites W2014366767 @default.
- W33296887 cites W2054870962 @default.
- W33296887 cites W2073369590 @default.
- W33296887 cites W2083452953 @default.
- W33296887 cites W2095327431 @default.
- W33296887 cites W2101465269 @default.
- W33296887 cites W2106720606 @default.
- W33296887 cites W2107812129 @default.
- W33296887 cites W2117105709 @default.
- W33296887 cites W2122904594 @default.
- W33296887 cites W2123666705 @default.
- W33296887 cites W2144025124 @default.
- W33296887 cites W2158134441 @default.
- W33296887 cites W2158734599 @default.
- W33296887 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3481147" @default.
- W33296887 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23112883" @default.
- W33296887 hasPublicationYear "2012" @default.
- W33296887 type Work @default.
- W33296887 sameAs 33296887 @default.
- W33296887 citedByCount "4" @default.
- W33296887 countsByYear W332968872014 @default.
- W33296887 countsByYear W332968872016 @default.
- W33296887 countsByYear W332968872022 @default.
- W33296887 countsByYear W332968872023 @default.
- W33296887 crossrefType "journal-article" @default.
- W33296887 hasAuthorship W33296887A5011595369 @default.
- W33296887 hasAuthorship W33296887A5011817630 @default.
- W33296887 hasAuthorship W33296887A5016787975 @default.
- W33296887 hasAuthorship W33296887A5017289995 @default.
- W33296887 hasAuthorship W33296887A5033029344 @default.
- W33296887 hasAuthorship W33296887A5033039101 @default.
- W33296887 hasAuthorship W33296887A5034570679 @default.
- W33296887 hasAuthorship W33296887A5036507892 @default.
- W33296887 hasAuthorship W33296887A5037389732 @default.
- W33296887 hasAuthorship W33296887A5061373605 @default.
- W33296887 hasAuthorship W33296887A5069256182 @default.
- W33296887 hasAuthorship W33296887A5082512772 @default.
- W33296887 hasConcept C121608353 @default.
- W33296887 hasConcept C126322002 @default.
- W33296887 hasConcept C141071460 @default.
- W33296887 hasConcept C143998085 @default.
- W33296887 hasConcept C197934379 @default.
- W33296887 hasConcept C203092338 @default.
- W33296887 hasConcept C2775930923 @default.
- W33296887 hasConcept C2777063308 @default.
- W33296887 hasConcept C2778375690 @default.
- W33296887 hasConcept C2778570526 @default.
- W33296887 hasConcept C2779194965 @default.
- W33296887 hasConcept C2779998722 @default.
- W33296887 hasConcept C2780210213 @default.
- W33296887 hasConcept C29730261 @default.
- W33296887 hasConcept C31760486 @default.
- W33296887 hasConcept C526805850 @default.
- W33296887 hasConcept C530470458 @default.
- W33296887 hasConcept C535046627 @default.
- W33296887 hasConcept C71924100 @default.
- W33296887 hasConcept C90924648 @default.
- W33296887 hasConceptScore W33296887C121608353 @default.
- W33296887 hasConceptScore W33296887C126322002 @default.
- W33296887 hasConceptScore W33296887C141071460 @default.
- W33296887 hasConceptScore W33296887C143998085 @default.
- W33296887 hasConceptScore W33296887C197934379 @default.
- W33296887 hasConceptScore W33296887C203092338 @default.
- W33296887 hasConceptScore W33296887C2775930923 @default.
- W33296887 hasConceptScore W33296887C2777063308 @default.
- W33296887 hasConceptScore W33296887C2778375690 @default.
- W33296887 hasConceptScore W33296887C2778570526 @default.
- W33296887 hasConceptScore W33296887C2779194965 @default.
- W33296887 hasConceptScore W33296887C2779998722 @default.
- W33296887 hasConceptScore W33296887C2780210213 @default.
- W33296887 hasConceptScore W33296887C29730261 @default.
- W33296887 hasConceptScore W33296887C31760486 @default.
- W33296887 hasConceptScore W33296887C526805850 @default.
- W33296887 hasConceptScore W33296887C530470458 @default.
- W33296887 hasConceptScore W33296887C535046627 @default.
- W33296887 hasConceptScore W33296887C71924100 @default.
- W33296887 hasConceptScore W33296887C90924648 @default.
- W33296887 hasLocation W332968871 @default.
- W33296887 hasOpenAccess W33296887 @default.
- W33296887 hasPrimaryLocation W332968871 @default.